Literature DB >> 15118792

[Primary gastric lymphoma].

P R Verreet1, W U Schmidt, F P Müller.   

Abstract

Primary gastric lymphoma derives from a secondary MALT system developing after a reaction of the immune system, e.g. following chronic gastritis induced by Helicobacter pylori. Morphologically, follicular hyperplasia is found in the gastric mucosa. The pathoetiologic model confirms the transformation of a malignant lymphoma from low grade to high grade by demonstrating increasing autonomous proliferation and, finally, uncontrolled dissemination. Modern diagnostic tools are essential for staging and planning an adequate therapeutic strategy. At present, the therapeutic strategies regarding primary lymphoma are under discussion. Nevertheless, the consensus of international medical and surgical associations still recommends surgical therapy with curative intention for low-grade malignant lymphomas staged I 2-II 2. In cases of high-grade malignant lymphoma, conservative therapy is supposed to be similarly successful. The recent success of noninvasive therapeutic concepts seems to justify the application of triple eradication medication in case of Hp infection as well as radio- and chemotherapy in low- and high-grade malignant lymphomas. However, in cases of nonremission or therapy-associated complications such as uncontrollable bleeding or tumor perforation, surgery is the only therapeutic option. Regarding the oncological aspects of lymphoma growth, surgery should then be performed in order to achieve R0 resection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118792     DOI: 10.1007/s00104-004-0890-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  14 in total

1.  Helicobacter pylori gastritis and gastric MALT-lymphoma.

Authors:  M Stolte
Journal:  Lancet       Date:  1992-03-21       Impact factor: 79.321

2.  Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.

Authors:  N A Willich; G Reinartz; E J Horst; G Delker; B Reers; W Hiddemann; M Tiemann; R Parwaresch; B Grothaus-Pinke; J Kocik; P Koch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

Review 3.  [MALT-lymphoma--surgical therapy].

Authors:  P R Verreet
Journal:  Praxis (Bern 1994)       Date:  1996-11-05

4.  Antibiotic treatment for low-grade gastric MALT lymphoma.

Authors:  A C Wotherspoon; C Doglioni; M de Boni; J Spencer; P G Isaacson
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

5.  Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis.

Authors:  T Radaszkiewicz; B Dragosics; P Bauer
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

6.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.

Authors:  A C Wotherspoon; C Doglioni; T C Diss; L Pan; A Moschini; M de Boni; P G Isaacson
Journal:  Lancet       Date:  1993-09-04       Impact factor: 79.321

7.  Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both?

Authors:  A Savio; G Franzin; A C Wotherspoon; G Zamboni; R Negrini; F Buffoli; T C Diss; L Pan; P G Isaacson
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

8.  The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach.

Authors:  B G Taal; J M Burgers; P van Heerde; A A Hart; R Somers
Journal:  Ann Oncol       Date:  1993-12       Impact factor: 32.976

9.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

10.  [Combined conservative treatment of localized stomach lymphoma].

Authors:  R Sonnen; A Calavrezos; H A Grimm; R Kuse
Journal:  Dtsch Med Wochenschr       Date:  1994-06-17       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.